2D-QSAR Modeling of Quinazoline Derivatives as EGFR Inhibitors for Colorectal Cancer

Simple item page
dc.contributor.authorRishab Pathak
dc.contributor.authorMayank Garhewal
dc.contributor.authorShani Yadav
dc.contributor.authorJyoti Prakash Panda
dc.contributor.authorAchal Mishra
dc.contributor.authorAyush Tiwari
dc.contributor.authorAvantika Agrawal
dc.contributor.authorShekhar Verma
dc.contributor.authorYogesh Vaishnav
dc.date.accessioned2026-10-07T10:34:36Z
dc.date.available2026-10-07T10:34:36Z
dc.date.issued2026-08-13
dc.description.abstractBackground: Globally, colorectal cancer represents one of the most common types of cancer, along with being one of the top 10 causes of cancer-related deaths. Epidermal Growth Factor Receptors (EGFRs) are a major target for colorectal cancer, and quinazoline derivatives have shown anticancer activity as EGFR inhibitors. Purpose: The objective of this research was the development of a two-dimensional quantitative structure–activity relationship model (2D-QSAR); that is, to develop a simple way to identify the structural components that help predict a potent compound with the highest predicted activity among the series of quinazoline derivatives for EGFR inhibitors for colorectal cancer. Methods: A dataset of 21 quinazoline derivatives was collected from the literature, molecular descriptors were calculated, and Partial Least Squares (PLS) regression was used to develop statistically significant QSAR models. Generated and validated using internal and external validation parameters. Results: Model-1 (RANDOM_70_30_SFB_PLS_TRIALS_2) showed the best statistical performance with r² = 0.6538, q² = 0.5314, pred-r² = 0.6940, and an F-test value of 22.6638. The descriptors SsssNcount and SaaCHE-index were identified as significant contributors to EGFR inhibitory activity, indicating that tertiary nitrogen count and charge distribution play crucial roles in determining biological potency. Conclusion: The developed 2D-QSAR model identified a potent compound with the highest predicted biological activity as an EGFR inhibitor for colorectal cancer.
dc.identifier.issn2321-2217
dc.identifier.issn2321-2225
dc.identifier.otherhttps://doi.org/10.15415/jptrm.2025.132008
dc.identifier.urihttps://dspace.chitkara.edu.in/handle/123456789/729
dc.language.isoen
dc.publisherChitkara University Publications
dc.subjectQuantitative structure-activity relationship
dc.subjectPartial least squares
dc.subjectCross-validated coefficient
dc.subjectQuinazoline
dc.subjectColon cancer
dc.title2D-QSAR Modeling of Quinazoline Derivatives as EGFR Inhibitors for Colorectal Cancer
dc.typeArticle

Files

Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
JPTRM Volume 13 Issue 2 008.pdf
Size:
1.45 MB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed to upon submission
Description:
Download

Collections

JPTRM Vol. 13 No. 2 (December 2025)